Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, UBS Group Analyst Says

Kymera Therapeutics (NASDAQ:KYMR) had its price objective increased by UBS Group from $90.00 to $128.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s price objective would suggest a potential upside of 48.65% from the company’s current price.

Several other analysts have also recently commented on KYMR. JPMorgan Chase & Co. upped their target price on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Piper Sandler upped their price target on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. Leerink Partners boosted their price target on Kymera Therapeutics from $70.00 to $118.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Finally, Bank of America upped their price target on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Kymera Therapeutics Trading Down 0.3%

NASDAQ:KYMR opened at $86.11 on Tuesday. The firm has a 50 day moving average of $78.75 and a 200-day moving average of $66.40. The stock has a market capitalization of $7.03 billion, a P/E ratio of -23.40 and a beta of 2.20. Kymera Therapeutics has a 1 year low of $19.44 and a 1 year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. During the same quarter last year, the business posted ($0.88) earnings per share. The business’s quarterly revenue was down 60.8% compared to the same quarter last year. As a group, analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In related news, COO Jeremy G. Chadwick sold 3,919 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total transaction of $334,290.70. Following the transaction, the chief operating officer directly owned 73,810 shares in the company, valued at approximately $6,295,993. The trade was a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jared Gollob sold 4,895 shares of Kymera Therapeutics stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $85.30, for a total value of $417,543.50. Following the sale, the insider owned 117,134 shares in the company, valued at $9,991,530.20. The trade was a 4.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 561,698 shares of company stock valued at $50,388,337. Company insiders own 16.01% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds have recently made changes to their positions in KYMR. Baker BROS. Advisors LP lifted its position in Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after buying an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after purchasing an additional 1,124,747 shares during the period. Vanguard Group Inc. increased its stake in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Finally, BVF Inc. IL increased its holdings in shares of Kymera Therapeutics by 6.6% during the second quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock valued at $240,138,000 after acquiring an additional 340,909 shares in the last quarter.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: UBS raised its price target to $128 and maintained a Buy rating, implying meaningful upside vs. the current level — this is a material analyst catalyst that can support upside interest. UBS price target raise
• Positive Sentiment: Analyst coverage and commentary highlight Kymera’s strong cash position (~$1.6B) and advancing degraders (KT‑621, KT‑579) into mid‑stage trials — these program milestones (2026–2027 catalysts) underpin medium‑term upside. Seeking Alpha pipeline write-up
• Positive Sentiment: Recent press roundups note broad analyst bullishness on select healthcare names including Kymera, which can help sustain investor interest from institutions and momentum traders. Globe and Mail analyst roundup
• Neutral Sentiment: Fundamentals remain mixed: recent quarterly results included a revenue shortfall and wider losses, which keep near‑term valuation sensitive to execution and clinical readouts. (Context referenced in analyst coverage above.) Seeking Alpha: financial context
• Negative Sentiment: Large director sale: Director Bruce Booth sold 81,866 shares (~$7.38M) — a ~10.8% reduction in his holding — which is a notable insider disposition that may create near‑term selling pressure or prompt investor questions about timing. Bruce Booth Form 4
• Negative Sentiment: Multiple executive sales: CFO Bruce Jacobs, COO Jeremy Chadwick and insider Jared Gollob completed several transactions across March 2–4 totaling tens of thousands of shares at prices in the mid‑$80s to ~$90 — cumulative insider selling raises short‑term supply concerns. Insider filings

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.